Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

HALO

Halozyme Therapeutics Inc

Feb 06 • 04:00PM ET

81.23

+2.81 3.58 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB XBI VBK FBT VXF MDY IBB XMHQ

Index	-	P/E	17.07	EPS (ttm)	4.76	Insider Own	1.13%	Shs Outstand	117.52M	Perf Week	13.28%
Market Cap	9.55B	Forward P/E	9.90	EPS next Y	8.21	Insider Trans	-20.56%	Shs Float	116.26M	Perf Month	8.15%
Enterprise Value	10.36B	PEG	0.31	EPS next Q	2.16	Inst Own	101.31%	Short Float	11.69%	Perf Quarter	18.93%
Income	595.49M	P/S	7.69	EPS this Y	51.34%	Inst Trans	2.12%	Short Ratio	6.03	Perf Half Y	30.81%
Sales	1.24B	P/B	18.94	EPS next Y	28.20%	ROA	27.45%	Short Interest	13.59M	Perf YTD	20.70%
Book/sh	4.29	P/C	13.61	EPS next 5Y	31.70%	ROE	124.50%	52W High	79.50 2.18%	Perf Year	40.95%
Cash/sh	5.97	P/FCF	15.86	EPS past 3/5Y	7.74% -	ROIC	45.67%	52W Low	47.50 71.01%	Perf 3Y	55.70%
Dividend Est.	-	EV/EBITDA	12.65	Sales past 3/5Y	31.82% 38.95%	Gross Margin	78.83%	Volatility	3.41% 3.21%	Perf 5Y	70.44%
Dividend TTM	-	EV/Sales	8.34	EPS Y/Y TTM	59.01%	Oper. Margin	59.33%	ATR (14)	2.37	Perf 10Y	823.07%
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	31.19%	Profit Margin	47.91%	RSI (14)	73.72	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.59	EPS Q/Q	36.06%	SMA20	11.15%	Beta	0.95	Target Price	78.00
Payout	0.00%	Debt/Eq	3.00	Sales Q/Q	22.12%	SMA50	16.66%	Rel Volume	1.00	Prev Close	78.42
Employees	350	LT Debt/Eq	1.59	Earnings	Nov 03 AMC	SMA200	24.87%	Avg Volume	2.25M	Price	81.23
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.51% 4.19%	Trades		Volume	2,245,436	Change	3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell	$56
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform	$70
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-05-26 09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
Feb-04-26 06:09PM	Silicon Motion Moves Higher On Rosy Outlook (Investor's Business Daily)
10:39AM	Google Stock: What The Buy Side Expects From Cloud Computing Business (Investor's Business Daily)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:21AM	Stock Market Today: Dow Rises Ahead Of Jobs Data; AMD Plunges On Earnings (Live Coverage) (Investor's Business Daily)
04:57PM	Loading…
Feb-03-26 04:57PM	Stock Market Today: Nasdaq Gets Hit Hardest As Techs Sink; Palantir Climbs After Earnings (Live Coverage) (Investor's Business Daily)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Feb-02-26 05:33PM	IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth (Investor's Business Daily)
12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-31-26 08:00AM	5 Stocks To Watch Trade Near Buy Points; Three Are Data Center Plays (Investor's Business Daily)
Jan-30-26 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jan-29-26 01:25PM	H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating (Insider Monkey)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
Jan-28-26 01:58PM	Halozyme Therapeutics Projects Sustained Growth Well Into 2040 (Benzinga)
12:02PM	Loading…
12:02PM	Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s (MarketBeat)
06:30AM	Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance (PR Newswire)
06:20AM	Halozyme buys a biotech startup; Cytokinetics launches heart drug (BioPharma Dive)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-22-26 09:52PM	TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance (Insider Monkey)
Jan-20-26 04:05PM	Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update (PR Newswire)
02:38PM	Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade (Insider Monkey)
Jan-19-26 07:20PM	Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty (Motley Fool)
Jan-18-26 10:36PM	Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks (StockStory)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE (PR Newswire)
11:04PM	Loading…
Jan-07-26 11:04PM	Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:25AM	Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. (Investor's Business Daily)
Jan-06-26 09:38AM	CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls (The Fly)
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Jan-01-26 03:30PM	Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 (StockStory)
Dec-31-25 11:41AM	Here's What Analysts Think About Halozyme Therapeutics (HALO) (Insider Monkey)
Dec-23-25 12:46PM	Halozyme Therapeutics Stock Sees Relative Strength Rating (Investor's Business Daily)
03:53AM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) (Zacks)
Dec-19-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Dec-18-25 12:48PM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Zacks)
07:00AM	U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-09-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-08-25 04:05PM	Jim Lang Elected to Halozyme's Board of Directors (PR Newswire)
Dec-06-25 09:50AM	The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. (Motley Fool)
Dec-05-25 09:56AM	Toast upgraded, PayPal downgraded: Wall Streets top analyst calls (TipRanks)
Dec-04-25 02:22PM	Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case (The Wall Street Journal)
01:26PM	Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany (PR Newswire)
09:53AM	Toast upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 12:02PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily)
11:30AM	Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? (Zacks)
Dec-01-25 12:00PM	What Makes Halozyme Therapeutics (HALO) a New Buy Stock (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
08:04AM	Meridian Growth Fund Trimmed Halozyme Therapeutics, Inc. (HALO) Following Appreciation (Insider Monkey)
Nov-27-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
09:07AM	This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside - Here's Why (Insider Monkey)
Nov-25-25 08:30AM	Halozyme to Participate in the 8th Annual Evercore Healthcare Conference (PR Newswire)
Nov-21-25 08:05AM	This Medical Technology Leader Sees Profit Growth Topping 44% (Investor's Business Daily)
Nov-18-25 08:50AM	Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery (PR Newswire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:45AM	Why I Keep Buying These 10 Incredible Growth Stocks (Motley Fool)
07:00AM	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PR Newswire)
Nov-12-25 02:43PM	Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? (Investor's Business Daily)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-07-25 01:20PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
08:30AM	FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma (PR Newswire)
Nov-06-25 11:37PM	Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-05-25 04:05PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
12:01AM	Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... (GuruFocus.com)
Nov-03-25 06:30PM	Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:37PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Oct-28-25 12:24PM	H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90 (Insider Monkey)
10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 12:45PM	Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings? (Zacks)
10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-25 10:01AM	Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025? (Zacks)
Oct-22-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-21-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:30AM	Halozyme to Report Third Quarter 2025 Financial and Operating Results (PR Newswire)
Oct-20-25 12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-17-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Oct-16-25 01:51PM	Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? (Zacks)
01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
10:49AM	Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? (Zacks)
Oct-06-25 09:40AM	Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? (Zacks)
Oct-02-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
07:25AM	Halozyme eyes microparticles in $900m Elektrofi acquisition (Pharmaceutical Technology)
01:35AM	Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target (Insider Monkey)
Oct-01-25 07:00AM	Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s (PR Newswire)
06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
02:36PM	AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease (Zacks)
Sep-26-25 12:18PM	Encompass Health Opens First Connecticut Rehab Hospital in Danbury (Zacks)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Option Exercise	12.07	10,000	120,700	718,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Sale	77.24	20,000	1,544,820	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Sale	76.12	20,000	1,522,317	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Sale	78.64	10,000	786,366	708,719	Feb 05 07:38 PM
Helen Torley	President, CEO, Director	Feb 03 '26	Proposed Sale	74.45	150,000	11,167,500		Feb 03 04:17 PM
Connaughton Bernadette	Director	Jan 05 '26	Sale	70.25	2,000	140,500	40,123	Jan 06 06:55 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '26	Option Exercise	0.00	7,611	0	38,424	Jan 06 06:55 PM
BERNADETTE CONNAUGHTON	Director	Jan 05 '26	Proposed Sale	70.31	2,000	140,620		Jan 05 04:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Option Exercise	0.00	9,326	0	17,000	Dec 19 05:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Sale	65.19	4,263	277,905	12,737	Dec 19 05:39 PM
Connaughton Bernadette	Director	Dec 01 '25	Sale	71.60	829	59,356	42,123	Dec 01 07:50 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Option Exercise	8.11	16,569	134,375	725,288	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Sale	68.92	16,569	1,141,925	708,719	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Sale	70.55	20,000	1,410,990	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Sale	69.13	20,000	1,382,600	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Sale	68.72	20,000	1,374,339	733,719	Nov 12 06:54 PM
Connaughton Bernadette	Director	Nov 10 '25	Sale	68.48	2,000	136,960	42,952	Nov 12 05:58 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Sale	75.35	20,000	1,507,024	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Sale	71.20	20,000	1,424,083	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Sale	69.03	20,000	1,380,638	733,719	Oct 03 06:00 PM
Connaughton Bernadette	Director	Oct 01 '25	Sale	75.24	2,000	150,481	44,952	Oct 01 06:29 PM
Helen Torley	President, CEO, Director	Oct 01 '25	Proposed Sale	73.34	136,569	10,015,970		Oct 01 04:26 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 22 '25	Sale	77.95	2,227	173,584	22,079	Sep 23 04:15 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Feb 06 • 04:00PM ET

23.56

+0.10 0.43 %

Healthcare • Biotechnology • USA • NASD

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR VTI XBI VB IWM FBT VBK VXF IBB SPSM

Index	RUT	P/E	15.16	EPS (ttm)	1.55	Insider Own	1.08%	Shs Outstand	169.15M	Perf Week	-6.25%
Market Cap	3.99B	Forward P/E	32.96	EPS next Y	0.71	Insider Trans	-3.76%	Shs Float	167.35M	Perf Month	-14.08%
Enterprise Value	3.19B	PEG	-	EPS next Q	0.13	Inst Own	100.05%	Short Float	5.00%	Perf Quarter	5.51%
Income	261.17M	P/S	3.81	EPS this Y	-39.88%	Inst Trans	-0.51%	Short Ratio	5.94	Perf Half Y	-3.44%
Sales	1.05B	P/B	4.34	EPS next Y	-12.58%	ROA	22.64%	Short Interest	8.37M	Perf YTD	-11.79%
Book/sh	5.42	P/C	4.71	EPS next 5Y	-7.12%	ROE	34.95%	52W High	28.35 -16.90%	Perf Year	20.20%
Cash/sh	5.01	P/FCF	20.15	EPS past 3/5Y	- -	ROIC	27.20%	52W Low	13.40 75.82%	Perf 3Y	24.46%
Dividend Est.	-	EV/EBITDA	29.45	Sales past 3/5Y	25.54% 23.08%	Gross Margin	91.92%	Volatility	4.51% 3.78%	Perf 5Y	-50.97%
Dividend TTM	-	EV/Sales	3.05	EPS Y/Y TTM	100.80%	Oper. Margin	9.02%	ATR (14)	0.96	Perf 10Y	7.33%
Dividend Ex-Date	-	Quick Ratio	2.94	Sales Y/Y TTM	12.69%	Profit Margin	24.94%	RSI (14)	33.44	Recom	1.85
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	113.29%	SMA20	-9.08%	Beta	0.67	Target Price	31.21
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	11.27%	SMA50	-10.58%	Rel Volume	1.67	Prev Close	23.46
Employees	654	LT Debt/Eq	0.05	Earnings	Feb 25 AMC	SMA200	1.93%	Avg Volume	1.41M	Price	23.56
IPO	May 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	142.91% 0.76%	Trades		Volume	2,355,879	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Citigroup	Buy	$33
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12

Show Previous Ratings

Feb-04-26 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
Feb-03-26 12:44PM	EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug (Benzinga) -5.24%
10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:05PM	Loading…
Feb-02-26 04:05PM	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union (Business Wire)
12:10PM	Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-13-26 02:06PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf (MarketBeat)
09:00AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-12-26 04:01PM	Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience (Bloomberg)
11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Dec-22-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Dec-18-25 04:05PM	Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (Business Wire)
08:00AM	Loading…
Dec-12-25 08:00AM	Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
Dec-03-25 09:17AM	Acadia to pivot to Alzheimers psychosis pipeline, accd to Wall Street analysts (Investing.com)
Nov-28-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-20-25 04:05PM	Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (Business Wire)
Nov-12-25 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
12:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:18PM	Loading…
04:18PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview (Business Wire)
12:04PM	Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y (Zacks)
Oct-29-25 10:00AM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
12:00PM	Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:55AM	Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-22-25 03:41PM	Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-15-25 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +6.78% -5.15%
Oct-09-25 11:40AM	QGEN vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 09:04AM	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders (Business Wire)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) -9.92%
09:32AM	Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges (Investor's Business Daily)
09:27AM	Lithium Americas, Oracle, Acadia Pharma: Trending Tickers (Yahoo Finance Video)
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
07:00AM	Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint (Business Wire)
02:12AM	ACADIA Pharmaceuticals (ACAD) Announces Interim Results From LOTUS study on DAYBUE (Insider Monkey)
Sep-12-25 04:05PM	Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology (Business Wire)
Sep-11-25 11:13AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome (Insider Monkey)
Sep-08-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
04:53AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial (Insider Monkey)
Aug-26-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-25-25 04:05PM	Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer (Business Wire)
Aug-21-25 09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-25 10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:19PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Aug-05-25 06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-04-25 04:05PM	Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer (Business Wire)
12:23PM	Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? (Zacks)
11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 11:40AM	GMAB vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-25 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 (Business Wire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-04-25 11:40AM	KMDA or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jul-03-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 08:23AM	Acadias very bullish sales forecast restores some confidence on Wall Street (BioPharma Dive)
Jun-25-25 08:00AM	Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers (Business Wire)
Jun-24-25 01:05PM	Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital (TipRanks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jun-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:40PM	US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication (Insider Monkey)
Jun-09-25 04:01PM	U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID (pimavanserin) Composition of Matter Patent (Business Wire)
Jun-06-25 11:31AM	Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report? (Zacks)
Jun-05-25 09:05AM	Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 (Business Wire)
May-29-25 04:05PM	Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-27-25 04:05PM	Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise (Business Wire)
May-20-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:52PM	Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday (Insider Monkey)
10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
11:40AM	GSK or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-17-25 01:36PM	Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer (TipRanks)
01:36PM	Acadia Nuplazid patent ruling removes key overhang, says BMO Capital (TipRanks)
May-16-25 01:43PM	Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation (Business Wire) +26.48%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks) +14.31%
08:03AM	Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 18 '25	Sale	23.69	10,262	243,114	53,338	Nov 19 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 18 '25	Sale	23.69	4,084	96,754	25,058	Nov 19 06:00 PM
Daly James M	Director	Nov 10 '25	Sale	22.37	30,000	670,983	4,041	Nov 12 06:00 PM
James M Daly	Director	Nov 10 '25	Proposed Sale	22.37	30,000	670,983		Nov 10 05:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Sep 15 '25	Sale	23.65	3,498	82,728	43,447	Sep 16 06:00 PM
GAROFALO ELIZABETH A.	Director	Sep 02 '25	Sale	25.98	1,600	41,560	25,382	Sep 03 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 18 '25	Sale	25.18	22,000	554,024	40,130	Aug 19 06:00 PM
Schneyer Mark C.	Officer	Aug 18 '25	Proposed Sale	25.33	22,000	557,260		Aug 18 04:31 PM
Brege Laura	Director	Jun 04 '25	Sale	21.78	14,446	314,634	15,095	Jun 05 06:01 PM
LAURA BREGE	Director	Jun 04 '25	Proposed Sale	21.78	14,446	314,638		Jun 04 04:35 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 16 '25	Sale	22.50	4,000	90,000	20,395	May 19 08:52 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 16 '25	Sale	25.00	2,000	50,000	62,130	May 19 08:50 PM
Schneyer Mark C.	Officer	May 16 '25	Proposed Sale	17.60	2,000	35,200		May 16 05:10 PM
Kihara James	Officer	May 16 '25	Proposed Sale	17.60	4,000	70,400		May 16 05:06 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '25	Sale	14.60	1,327	19,374	23,526	May 02 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '25	Sale	14.60	3,498	51,071	62,773	May 02 07:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '25	Sale	14.82	2,708	40,133	59,456	Apr 08 07:40 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '25	Sale	14.82	1,028	15,235	22,257	Apr 08 07:38 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '25	Sale	17.05	1,095	18,670	21,275	Mar 26 08:10 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	17.05	3,171	54,066	56,889	Mar 26 08:06 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM

HALO

Halozyme Therapeutics Inc

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience